Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study

作者：Jin‐Yuan Wang, Jingru Jiang, Sudan Peng, Jie Jiang, Zhonglin Liu, Jifu Cai, Jin Hui Li, Yi Li, Ying Chen, Honghong Li, Xiaoming Rong, Lei He, Li Ren, Ji Yan, Sha Li, Yingying Zhu, Songhua Xiao, Yamei Tang, Yongteng Xu · 发表于：The Journal of Headache and Pain · 年份：2025 · DOI：10.1186/s10194-025-02197-8 · 被引用次数：7 · 研究领域：Migraine and Headache Studies、Traumatic Brain Injury Research、Neurological Complications and Syndromes

BACKGROUND: Migraine imposes a substantial global burden, with unmet patient-centered therapeutic needs. Rimegepant, a CGRP receptor antagonist, has trial-proven efficacy, but real-world evidence for its dual acute and preventive use in Chinese migraine populations is limited. This study evaluated its effectiveness in Chinese patients using patient-reported outcomes. METHODS: A multicenter, single-arm, prospective, non-interventional observational study was conducted across five hospitals in the Guangdong-Hong Kong-Macao Greater Bay Area, China. A total of 120 adult migraine patients who were prescribed rimegepant for either acute (AT) or preventive treatment (PT) were enrolled. Patient-reported outcomes were assessed at baseline and after 4 weeks using Headache Impact Test (HIT-6), Treatment Satisfaction Questionnaire for Medication (TSQM), the European Five-Dimension Five-Level Health Scale (EQ-5D-5L) and the Work Productivity and Activity Impairment Questionnaire - General Health (WPAI-GH). We employed the Wilcoxon signed-rank test for within-group comparisons of pre- and post-treatment scale scores, with statistically significant defined as a two-tailed p-value < 0.05. RESULTS: A total of 120 migraine patients meeting all inclusion criteria were enrolled but 12 potential participants (10.0%) did not initiate rimegepant therapy. The study was completed by 108 patients (median age 37.0 (31.5,46.0) years; 83% female), including 89 in the AT group and 19 in the PT group. Afte...